Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
about
A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's DiseaseAnti-TNF-alpha therapy and systemic vasculitis.Behçet's Uveitis.Current approach in the diagnosis and management of panuveitis.Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.Immunopathogenesis of ocular Behçet's diseaseLong-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data.Prevention of endotoxin-induced uveitis in rats by plant sterol guggulsteroneThe use of biologic agents in the treatment of ocular manifestations of Behcet's disease.Preventive effects of ethyl pyruvate on endotoxin-induced uveitis in rats.Retinal vasculitis: a novel paradoxical effect of anti-TNFα?New Evidence-Based Treatment Approach in Behçet's Disease.Clinical trials in noninfectious uveitisEfficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patientsAdalimumab in the therapy of uveitis in childhoodOutcome measures used in clinical trials for Behçet syndrome: a systematic review.Adalimumab for sight-threatening uveitis in Behçet's disease.Biologic therapies for inflammatory eye disease.Update on the diagnosis and management of Behçet's disease.Interferons and their potential in the treatment of ocular inflammation.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.Update on the therapy of Behçet disease.Emerging biologics in the treatment of uveitis.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Evaluation of current therapeutic strategies in Behçet's disease.Biological agents for the treatment of uveitis.Biologic agents in inflammatory eye disease.Light on the horizont: biologicals in Behçet uveitis.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.Current and future treatments for Behçet's uveitis: road to remission.Approaches to immunosuppression in Behçet's disease.Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.Therapy of ocular Behçet disease.Use of infliximab and other biologics in Behçet disease.Ocular Involvement of Behçet's Syndrome: a Comprehensive Review.Aldose reductase inhibition prevents endotoxin-induced uveitis in rats.A Major Review: Current Aspects of Ocular Behçet's Disease in Japan.Management of severe complications in Behçet's disease with TNF inhibitors.
P2860
Q26777598-793F6AA1-C4FD-4AF0-A5E4-74AC92721618Q27687590-835FDA8E-0E3D-4537-BA17-B592986DFDDEQ33559788-8505BAC7-4623-43AD-A228-E877999078CDQ33737954-3429C0A0-D812-4BD2-B561-7218AB16473DQ33757440-897E87F2-463D-4322-B5F2-D9AB151183FBQ33908937-8EB3DAEC-CC7B-4EE2-B1F9-0D234000EA01Q34041295-90F3C5C2-B6C2-4B21-B930-A639A4A2CF72Q34142185-9A68A200-7D9C-4ECA-81DF-27C96B9130C9Q34161028-C8037740-F017-4AC2-B1E0-9321C7B46F9DQ34220221-8E2F5BB2-44E6-48FD-A19C-F80737E6197BQ35221278-701B107B-D770-4581-825F-859F51301D4CQ35229113-9C0C40E0-0A5C-4B4B-88EE-2A9A6CB3BD1EQ35295186-DC0A8E8D-1CC4-4E49-99FD-A8CA4C522508Q35681664-ECC5AC63-F7AA-49A0-B83D-E65E440E1F55Q35699360-CBB841CA-FEA5-4786-AE89-E9C34D83AAC8Q35763157-970FA028-8057-48F2-9501-15A56EDF9B46Q35868282-D871A833-DE68-4067-8947-24A4DEBA7411Q36443513-8955E6E1-3F4A-457F-A8E6-B36D56A7CFE8Q36501675-BB992015-45A3-43F9-9BFA-04D6C58C1E3CQ37301191-2A02BCF4-997E-4454-99B0-9AE35B039DDAQ37406596-6BBEC295-9473-44CB-B8D2-9836C52D68D4Q37650221-C081A4FB-BF94-4F18-A00A-0AC7ACD7609EQ37684328-571C67F4-D132-4673-8EE1-A0A78C1B7CA8Q37712230-1565BD3A-495E-40B1-B3AB-9815DE08078CQ37754665-C471DAE7-BB96-4506-AF15-3B583CC684B5Q37756167-57D21571-3988-4E73-9A63-59F97BE33EA1Q37788987-3DBE8CA0-91FD-44A9-83F1-80939860AF69Q37984565-D54DB841-1048-4582-978C-4BC4804097D9Q37997772-2230E841-D829-4FC1-865F-C6DF21661FB3Q38004097-BD0237B8-68D3-48C6-95A7-0ED0A24721AFQ38074446-27EB8932-ECF5-44D4-9C79-45FE5213E93AQ38111308-188F5452-90D0-4366-A02E-C2CE32190EBFQ38119551-5174D8EB-116A-459E-B785-B14B2AB4F349Q38152971-A4D4CF12-7DCB-4AD8-AB4D-1C4EE1E49B06Q38174652-102AA4A6-8391-4B34-A882-99E3D13CA3ABQ38180747-129726C7-9AED-43FC-958F-E87246155BE2Q38211813-F362DF4D-BDE6-431E-A27C-0E573BDEF409Q38307889-CA251138-9CCB-4FD0-937D-98438A44E221Q38545948-26070507-8254-475A-8F6D-18F5A0693A9FQ38786414-FF04EF90-C57F-4976-8F1F-40E2C61808FB
P2860
Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Efficacy of infliximab in the ...... disease: an open-label trial.
@en
Efficacy of infliximab in the ...... disease: an open-label trial.
@nl
type
label
Efficacy of infliximab in the ...... disease: an open-label trial.
@en
Efficacy of infliximab in the ...... disease: an open-label trial.
@nl
prefLabel
Efficacy of infliximab in the ...... disease: an open-label trial.
@en
Efficacy of infliximab in the ...... disease: an open-label trial.
@nl
P2093
P356
P1476
Efficacy of infliximab in the ...... disease: an open-label trial.
@en
P2093
Abdulbaki Mudun
Esen Kasapoglu
Ilknur Tugal-Tutkun
Meri Urgancioglu
Murat Inanc
Sevil Kamali
P2860
P304
P356
10.1002/ART.21231
P577
2005-08-01T00:00:00Z